Mark Alan Goldberg, SVP, Medical&Regulatory Affairs at SYNAGEVA BIOPHARMA CORP (GEVA), sold 7,000 shares at $64.61 ($450K) on 2013-10-01, disclosed to the SEC on 2013-10-03.
Scheduled sale ($450k) by SVP, Medical&Regulatory Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $63.97 | 3,230 | $207K | 45.9% |
| 2 | $64.61 | 3,770 | $244K | 54.1% |
| Total | $64.31 avg | 7,000 | $450K | 100% |
| Filing → |
| BPMC | SELL | 2020-12-22 | $654K | — | Filing → |
| BPMC | SELL | 2020-12-15 | $627K | — | Filing → |
| BPMC | SELL | 2020-12-03 | $600K | — | Filing → |